MENU
BIB
ETF ticker: NASDAQ
PRICE
CHANGE
NET ASSETS

BIB stock forecast, quote, news & analysis

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®... Show more

Category: #Trading
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for BIB with price predictions
Nov 10, 2026

Momentum Indicator for BIB turns positive, indicating new upward trend

BIB saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 88 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BIB just turned positive on October 20, 2026. Looking at past instances where BIB's MACD turned positive, the stock continued to rise in 45 of 48 cases over the following month. The odds of a continued upward trend are 90%.

BIB moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BIB crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.

Following a +10.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIB advanced for three days, in 292 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

BIB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 204 of 219 cases where BIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Guardant Health (NASDAQ:GH), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

Market Cap

The average market capitalization across the ProShares Ultra Nasdaq Biotechnology (BIB) ETF is 9.07B. The market cap for tickers in the group ranges from 25.61M to 248.92B. AMGN holds the highest valuation in this group at 248.92B. The lowest valued company is AARD at 25.61M.

High and low price notable news

The average weekly price growth across all stocks in the ProShares Ultra Nasdaq Biotechnology (BIB) ETF was 115%. For the same ETF, the average monthly price growth was 111%, and the average quarterly price growth was 407%. PEPG experienced the highest price growth at 87%, while VCYT experienced the biggest fall at -52%.

Volume

The average weekly volume growth across all stocks in the ProShares Ultra Nasdaq Biotechnology (BIB) ETF was 20%. For the same stocks of the ETF, the average monthly volume growth was 10% and the average quarterly volume growth was -27%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 45
Price Growth Rating: 55
SMR Rating: 86
Profit Risk Rating: 82
Seasonality Score: 6 (-100 ... +100)
Momentum Indicator for BIB turns positive, indicating new upward trend